• EMA’s CHMP began a phased review of Revolution Medicines’ pancreatic cancer drug candidate daraxonrasib, speeding assessment ahead of a full filing.
• Daraxonrasib also entered EMA’s Cancer Medicines Pathfinder project, citing high unmet need.
• A rolling U.S. FDA NDA submission under the Commissioner’s National Priority Voucher pilot program is nearing completion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607070923OMX_____CNEWS_EN_GNW9758181_en) on July 07, 2026, and is solely responsible for the information contained therein.